AstraZeneca (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. AstraZeneca (Sweden)瑞典14
2. AstraZeneca (United Kingdom)英国10
3. Bayer (Germany)德国4
4. Pfizer (United States)美国3
5. Merck KGaA, Darmstadt (Germany)德国2
6. Bristol-Myers Squibb (United States)美国2
7. Henry Ford Health美国2
8. Columbia University Irving Medical Center美国2

按月发文

逐年被引

最新文献

1. 1
   Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?Drug Safety20251
2. 2
   Correspondence on ‘Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries’ by Sadeket alEmergency Medicine Journal20240
3. 3
   A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the presentExpert Opinion on Drug Safety20247
4. 4
   Validation of a Natural Language Machine Learning Model for Safety Literature SurveillanceDrug Safety20233
5. 5
   Identification of urgent gaps in public and policymaker knowledge of heart failure: Results of a global surveyBMC Public Health202314
6. 6
   Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksDrug Safety20230
7. 7
   Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingDrug Safety20228
8. 8
   Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksDrug Safety202215
9. 9
   Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingDrug Safety20227
10. 10
    Patient Global Impression of Benefit–Risk (PGI-BR): Incorporating Patients’ Views of Clinical Benefit–Risk into Assessment of New MedicinesDrug Safety20215

高被引文献

1. 1
   Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on BenralizumabDrug Safety202085
2. 2
   Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double‐blind, Placebo‐controlled Study (ENERGIZE)Academic Emergency Medicine202085
3. 3
   Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic ReviewDrug Safety201878
4. 4
   Literature review of visual representation of the results of benefit–risk assessments of medicinal productsPharmacoepidemiology and Drug Safety201536
5. 5
   Unmet needs in the management of exacerbations of chronic obstructive pulmonary diseaseInternal and Emergency Medicine202132
6. 6
   Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled AsthmaDrug Safety201921
7. 7
   Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA StudiesDrug Safety202119
8. 8
   Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksDrug Safety202215
9. 9
   Identification of urgent gaps in public and policymaker knowledge of heart failure: Results of a global surveyBMC Public Health202314
10. 10
    Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingDrug Safety20228

主要发表期刊

研究主题